A Phase 3 interventional study of TH07 and TH07 in Androgenic Alopecia, sponsored by Triple Hair Inc. Recruiting at 1 site in Canada. Open to male participants aged 18 Years to 49 Years. Per ClinicalTrials.gov, last updated 2026-03-16.
Sponsored by Triple Hair Inc · Phase 3, Interventional, and Treatment
The goal of this clinical trial is to learn whether a new topical solution, TH07, can help treat androgenic alopecia in men and to learn more about its safety. Participants will be asked to apply either the TH07 solution, a standard hair growth treatment (Minoxidil 5%), or a placebo every day for 24 weeks. At the end of the study, hair growth will be compared in each group to determine which treatment is most effective at increasing hair count.
The MATT study is a Phase III clinical trial designed to evaluate the safety and effectiveness of a new topical hair growth treatment called TH07.
TH07 is a combined topical spray solution containing three active ingredients commonly used to treat hair loss: Minoxidil (5%) Finasteride (0.1%) and Latanoprost (0.03%). The study plans to enroll 420 men aged 18 to 49 years old across up to 10 clinical sites.
Participants will be randomly assigned to one of four groups to receive either TH07 (once or twice daily), a standard Minoxidil solution, or a placebo.
The treatment will be applied daily (once or twice) for 24 weeks.
Willing to comply with the following restrictions for the duration of trial participation:
Participation in any other drug or device trials during the course of this trial.
Note: However, the following shall be permissible:
Exclusion Criteria:
History of scalp treatment including though not limited to any of the following:
5-Any other surgical treatment for hair loss
Any of the following hair styles:
1.Shaved scalp. 2-Use of occlusive wig, hair extensions, non- breathable wigs.
All participants in Arm A will apply TH07 topical solution twice a day for 24 weeks
Drug: TH07
All participants in Arm B will apply TH07 topical solution once a day and Placebo topical solution once a day for 24 weeks
Drug: TH07
All participants in Arm C will apply Minoxidil 5% topical solution twice a day for 24 weeks
Drug: Minoxidil 5% Topical Solution
All participants in Arm D will apply Placebo topical solution twice a day for 24 weeks
Other: Placebo
TH07 (5%Minoxidil, 0.1%Finasteride, 0.03%Latanoprost); topical solution; twice a day
* TH07 (5%Minoxidil, 0.1%Finasteride, 0.03%Latanoprost); topical solution; once a day * Placebo; topical solution; once a day
Minoxidil 5%; topical solution; twice a day
Placebo; topical solution; twice a day
Non-vellus hair count
Number of hair in the matched target area measured by phototrichogram
Time frame: Baseline and week 24
Hair diameter and cumulative hair thickness
hair thickness is defined as average hair diameter \* hair count in the matched target area / size of matched target area (mm/cm2)
Time frame: Baseline and week 24
Subject-reported improvement
self-assessment questionnaire
Time frame: week 24
Non-vellus hair count
in the matched target area by phototrichogram between TH07 twice daily, TH07 once daily, and placebo
Time frame: Baseline and week 24
Incidence of treatment related adverse events.
reporting of adverse events and serious adverse events
Time frame: through study completion, average 28 weeks
Plan to share: No
No publications or documents are linked to this record.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.